BGC Beats Q3 2026 Estimates as Revenue Rises 15% to $832.6M

BGC (BGC) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $832.6 million, up 15% from a year earlier, above the $824.8 million estimate, and adjusted EPS was $0.34, up 17% from a year earlier, above the $0.34 estimate.

Q3 2026 scorecard

By our calculation, revenue was $7.8 million above the estimate and adjusted EPS was $0.01 above it. The QoQ column compares with the previous quarter's revenue of $845.5 million and adjusted EPS of $0.35. The YoY column compares with $722.8 million and $0.29 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 4 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 5 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $722.8 million, $756.4 million, $955.5 million, $845.5 million and $832.6 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.34 and revenue of $831.2 million next quarter, based on 1 analyst.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 15% increase to $832.6 million.
• Estimate record. Whether BGC extends a record of beating EPS estimates in 4 of its last 8 reports.
• Related coverage. See our reports on Novavax, Globalstar, Intellia Therapeutics and Insight Enterprises.

Sources: Results are from BGC's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from BGC's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.